Furthermore, EGCG selectively decreased MGMT levels in glioblastoma multiforme cells by preventing translocation of β-catenin to the nucleus, thereby avoiding the removal of temozolomide-produced O6-methylguanine and helping to resensitize cells resistant to this drug. This evidence concerns the gene MGMT and glioblastoma.